Investors Sell Shares of Celgene (CELG) on Strength (CELG)

Investors sold shares of Celgene Co. (NASDAQ:CELG) on strength during trading on Friday. $98.31 million flowed into the stock on the tick-up and $161.68 million flowed out of the stock on the tick-down, for a money net flow of $63.37 million out of the stock. Of all companies tracked, Celgene had the 11th highest net out-flow for the day. Celgene traded up $0.45 for the day and closed at $87.40

A number of equities research analysts recently issued reports on CELG shares. BidaskClub downgraded shares of Celgene from a “buy” rating to a “hold” rating in a report on Thursday, September 13th. UBS Group set a $94.00 target price on shares of Celgene and gave the company a “buy” rating in a report on Saturday, October 27th. Wells Fargo & Co lowered their target price on shares of Celgene from $90.00 to $84.00 and set a “market perform” rating for the company in a report on Thursday, January 3rd. ValuEngine upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a report on Friday, January 4th. Finally, Morgan Stanley lowered their target price on shares of Celgene from $93.00 to $88.00 and set an “equal weight” rating for the company in a report on Wednesday, December 19th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $110.17.

The firm has a market capitalization of $61.19 billion, a PE ratio of 12.78, a price-to-earnings-growth ratio of 0.46 and a beta of 1.44. The company has a debt-to-equity ratio of 4.06, a current ratio of 2.13 and a quick ratio of 1.99.

Celgene (NASDAQ:CELG) last released its earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.02 by $0.27. The company had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. On average, equities research analysts anticipate that Celgene Co. will post 7.45 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CELG. Csenge Advisory Group bought a new position in shares of Celgene in the third quarter valued at approximately $90,000. Global Trust Asset Management LLC lifted its holdings in shares of Celgene by 217.9% in the fourth quarter. Global Trust Asset Management LLC now owns 1,459 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 1,000 shares in the last quarter. Atlantic Trust LLC bought a new stake in Celgene during the second quarter worth $101,000. Moneta Group Investment Advisors LLC lifted its holdings in Celgene by 2,688.6% during the second quarter. Moneta Group Investment Advisors LLC now owns 10,290 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 9,921 shares during the period. Finally, Harvest Fund Management Co. Ltd bought a new stake in Celgene during the third quarter worth $132,000. 72.80% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Investors Sell Shares of Celgene (CELG) on Strength (CELG)” was first reported by WKRB News and is owned by of WKRB News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.wkrb13.com/2019/01/12/investors-sell-shares-of-celgene-celg-on-strength-celg.html.

About Celgene (NASDAQ:CELG)

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

See Also: Price to Earnings Ratio (PE) Basics

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply